Key result
Deletion of dipeptidyl peptidase I (DPPI) in diabetic mice significantly improved left ventricular ejection fraction (64.2% vs 58.5%) and reduced cardiac inflammation, apoptosis, and fibrosis.
Why the study?
The molecular mechanism linking inflammation to diabetic cardiomyopathy is incompletely understood, prompting investigation into the role of inflammatory serine proteases.
Does DPPI deletion prevent the development of diabetic cardiomyopathy in a mouse model of type 1 diabetes?
Does DPPI deletion prevent the development of diabetic cardiomyopathy in a mouse model of type 1 diabetes?
Absolute Event Rate: 64.2% vs 58.5%
p-value: p=<0.0446
DPPI deletion attenuates the development of diabetic cardiomyopathy in a type 1 diabetes mouse model by reducing inflammatory serine protease activation, apoptosis, and fibrosis.
DPPI deletion attenuates DCM progression in T1DM mice; leaves open whether ISP targeting translates to human diabetic cardiomyopathy.
BACKGROUND/AIMS: Diabetic cardiomyopathy (DCM) is characterized by structural and functional alterations that can lead to heart failure. Several mechanisms are known to be involved in the pathogenesis of DCM, however, the molecular mechanism that links inflammation to DCM is incompletely understood. To learn about this mechanism, we investigated the role of inflammatory serine proteases (ISPs) during the development of DCM. METHODS: Eight weeks old mice with deletion of dipeptidyl peptidase I (DPPI), an enzyme involved in the maturation of major ISPs, and wild type (WT) mice controls were injected with streptozotocin (50 mg/kg for 5 days intraperitoneally) and studied after 4, 8, 16, and 20 week after induction of type 1 diabetes mellitus (T1DM). Induction of diabetes was followed by echocardiographic measurements, glycemic and hemoglobulin A1c profiling, immunoblot, qPCR, enzyme activity assays, and immunohistochemistry (IHC) analysis of DPPI, ISPs, and inflammatory markers. Fibrosis was determined from left ventricular heart by Serius Red staining and qPCR. Apoptosis was determined by TUNEL assay and immunoblot analysis. RESULTS: In the diabetic WT mice, DPPI expression increased along with ISP activation, and DPPI accumulated abundantly in the left ventricle mainly from infiltrating neutrophils. In diabetic DPPI-knockout (DPPI-KO) mice, significantly decreased activation of ISPs, myocyte apoptosis, fibrosis, and cardiac function was improved compared to diabetic WT mice. In addition, DPPI-KO mice showed a decrease in overall inflammatory status mediated by diabetes induction which was manifested by decreased production of pro-inflammatory cytokines like TNF-α, IL-1β and IL-6. CONCLUSION: This study elucidates a novel role of ISPs in potentiating the immunological responses that lead to the pathogenesis of DCM in T1DM. To the best of our knowledge, this is the first study to report that DPPI expression and activation promotes the inflammation that enhances myocyte apoptosis and contributes to the adverse cardiac remodeling that subsequently leads to DCM.
No takes yet. Share an insight, caveat, or question.
Kolpakov et al. (2019) studied Diabetic Cardiomyopathy. Dipeptidyl peptidase I (DPPI) deletion vs. Wild-type was evaluated on Left ventricular ejection fraction (LV EF) at 4 weeks (p=<0.0446). Deletion of dipeptidyl peptidase I (DPPI) in diabetic mice significantly improved left ventricular ejection fraction (64.2% vs 58.5%) and reduced cardiac inflammation, apoptosis, and fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: